Neuraxis, Inc.

Day range

$7.30 – $7.51

Open

$7.39

Prev close

$7.40

Volume

70.51K

Market cap

$92.93M

Shares out

12.56M

P/E

—

P/S

17.48

P/B

13.80

P/FCF

—

ROE

-125.5%

ROA

-84.6%

Debt/Equity

0.01

Div yield

0.00%

As of Oct 23, 2026

• Dividend declarationOct 14, 2026

  On October 14, 2026, the Board of Directors of Neuraxis, Inc. authorized and the Company declared a stock dividend on the Company's Series B Preferred Stock ... for the third quarter of 2026. ... The Third Quarter Dividend will be payable on October 30, 2026, to holders of record ... as of the close of business on October 26, 2026.

• Executive compensation changeAug 19, 2026

  On August 13, 2026, following the approval of the Compensation Committee of the Board of Directors (the 'Compensation Committee'), the Company granted (i) 193,329 RSUs to Brian Carrico, (ii) 141,479 RSUs to Timothy Henrichs, Chief Financial Officer of the Company, (iii) 133,341 RSUs to Adrian Miranda, and (iv) 135,906 RSUs to Thomas Carrico, under the 2022 Plan. The RSUs vest in three equal annual installments over a three-year period.

• Equity compensation grantJun 12, 2026

  The proposal regarding the Neuraxis, Inc. 2025 Employee Stock Purchase Plan was approved as follows: Votes For 7,572,343... the Board approved changing Section 5(c) of the ESPP so that no employee may receive purchase rights pursuant to the ESPP if, immediately after grant, the employee would own 10% or more of the Company's voting power or value.

• Underwriting agreementApr 22, 2026

  the Company entered into an At The Market Offering Agreement (the "Agreement") with Craig-Hallum Capital Group LLC (the "Sales Agent") under which the Company may offer and sell, from time to time at its sole discretion, shares of its $0.001 par value common stock

• Preliminary resultsApr 21, 2026

  On April 21, 2026, Neuraxis, Inc. (the "Company"), issued disclosure that, on a preliminary unaudited basis, the Company expects its cash and cash equivalents to be approximately $7.1 million as of March 31, 2026. The Company expects its net sales to be approximately $1.6 million for the three months ended March 31, 2026, as compared to approximately $0.9 million for the three months ended March 31, 2025. On a preliminary unaudited basis, the Company expects its gross profit to be approximately $1.4 million, and its operating loss to be approximately $1.7 million, for the three months ended March 31, 2026.

Days to cover

1.6

Short interest

372.81K

Avg volume

236K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Is Kodak having a "Kodak moment?" 2 watchlist stocks.
  neutralZacks Investment Research· Sep 12, 2026
• NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
  neutralGlobeNewswire Inc.· May 5, 2026
• NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population
  positiveGlobeNewswire Inc.· Oct 24, 2025
• NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025
  positiveGlobeNewswire Inc.· May 5, 2025
• NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
  positiveGlobeNewswire Inc.· Mar 12, 2025